|   From the Trenches

SPAC downpour continues

Holy cow, have we seen the rain lately – both downpours outside and a downpour of SPAC activity.

By Sam Truex, Venture Partner at Atlas Venture, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   From the Trenches

Playing To Win: Building A Position Of Strength In Biotech

When I play board games, I play to win. That requires thinking several moves ahead. In the game Risk, for instance, it’s not enough to just conquer Australia. If you want to use the continent as a launch pad to take over the world, you need to design and execute on a long-term strategy.

By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC

Read more.


  |   From the Trenches

Targeted Protein Degradation: The First Proof-of-Mechanism in a Randomized, Placebo-Controlled Study

The inherent ability to combine the power of genetic-like knockdown with the flexibility of small molecules; the power to drug classes of targets that have been elusive to other therapeutic modalities; the use of affinity rather than occupancy-based catalysis – the promise of these advantages has made targeted protein degradation one of the most exciting new therapeutic modalities of the past 30 years.

By Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera Therapeutics, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   In the News

Hitting landmark milestone, Intellia shows CRISPR can edit genes directly in patients

In a landmark study, researchers successfully used CRISPR to directly edit DNA in humans, a milestone that could pave the way for treatments for scores of serious genetic and non-genetic diseases.

Read more.


  |   From the Trenches

The First Born

I was in the passenger seat, trying desperately not to reach for the grab handle, saying reassuring things but thinking ‘those mailboxes are really close’.

By Aoife Brennan, CEO of Synlogic, as part of the From The Trenches feature of LifeSciVC

Read more.